Stay updated with breaking news from Gpp baladol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PNB Vesper provides potential option to save hospitalised COVID-19 patients globally PNB Vesper provides potential option to save hospitalised COVID-19 patients globally 12 February 2021 | News Source credit: Shutterstock PNB Vesper, a leading Kerala based life sciences company, has announced that it has successfully completed the phase 2 clinical trials of its proprietary drug PNB-001 (GPP-Baladol) on COVID-19 patients. The company had received approval from the Drug Controller General of India (DCGI) to conduct the Phase 2 Clinical trial of GPP-BALADOL in COVID-19 moderate patients with oxygen support in September 2020. The clinical trial was initiated in November 2020 at BJ Government Medical College and Sassoon General Hospital Pune, and Victoria Medical College and Research Institute, Bengaluru. The clinical trial report will now be submitted to DCGI on February 22, 2021. ....
Updated Feb 12, 2021 | 19:20 IST PNB Vesper, a leading Kerala based Life Sciences Company, today announced that it has successfully completed the phase 2 clinical trials of its proprietary drug PNB-001 (GPP-Baladol) on COVID-19 patients. Representational Image Key Highlights Clinical trial report to be submitted to Drug Controller General of India on 22nd February 2021 PNB Vesper is a research-based bio-pharmaceutical organization that is determined to discover drugs for serious diseases The drug molecule developed by the PNB Vesper team for the treatment of COVID-19 has already been patented and the related Intellectual Property Rights (IPRs) have been secured by PNB Vesper in the US, Europe and rest of the world ....